Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04419467 · ClinicalTrials.gov registry record · Phase 2
Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
A Phase 2 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT04419467 is a Phase 2 study that has completed, run by CSL Behring. The registered enrollment target is 114 participants.
The verdict
NCT04419467, a Phase 2 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
This phase 2a, double-blind, randomized, placebo-controlled study will assess the efficacy, safety, tolerability, and pharmacokinetics (PK), of repeat doses of CSL346 in subjects with diabetic kidney disease (DKD) and albuminuria receiving standard of care treatment.
Interventions
- DRUG Placebo
- BIOLOGICAL CSL346
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2020-09-14 |
| Est. Completion | 2022-10-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04419467
The ClinicalTrials.gov registry entry for NCT04419467 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04419467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04419467 about?
NCT04419467 is a clinical study titled "Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease". This phase 2a, double-blind, randomized, placebo-controlled study will assess the efficacy, safety, tolerability, and pharmacokinetics (PK), of repeat doses of CSL346 in subjects with diabetic kidney disease (DKD) and albuminuria receiving standard of care treatment.
What is the current status of trial NCT04419467?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2020-09-14. Estimated completion is 2022-10-24.
What interventions are being tested in trial NCT04419467?
The interventions under investigation include: Placebo (DRUG), CSL346 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04419467?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.